Immuneering Announces Participation in September Investor Conferences
August 25 2022 - 6:50AM
Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company
using translational bioinformatics to advance a pipeline of product
candidates designed to benefit large populations of patients with
cancer and other diseases, today announced that management will
participate in two September investor conferences to share
commentary around the Company’s pipeline, platform, and business
strategy. Presenting will be Ben Zeskind, Ph.D., Co-Founder, and
Chief Executive Officer and Brett Hall, Ph.D., Chief Scientific
Officer.
Immuneering will participate in the following conferences:
Wells Fargo 2022 Healthcare Conference, Boston,
MAFormat: One-on-one meetingsDate: September 8, 2022
Morgan Stanley 20th
Annual Global Healthcare Conference, New York,
NYFormat: Fireside ChatDate: September 14, 2022Time: 2:05
pm ETThe audio portion of the presentation will be webcast live and
archived for 30 days in the Investor Relations section of
Immuneering’s website at Events & Presentations | Immuneering
Corporation.
About Immuneering CorporationImmuneering
aims to improve patient outcomes by advancing a pipeline of
product candidates designed to benefit large populations of
patients with cancer and other diseases, developed
using its translational bioinformatics
platform. Immuneering has more than a decade of
experience applying translational bioinformatics to generate
insights into drug mechanism of action and patient treatment
response. Building on this
experience, Immuneering's disease-agnostic discovery
platform enables the company to create product candidates
based on 1) biological insights that are both counterintuitive and
deeply rooted in data, and 2) novel
chemistry. Immuneering's lead product candidate,
IMM-1-104, aims to achieve pan-KRAS/NRAS activity that selectively
impacts cancer cells to a greater extent than healthy cells.
IMM-1-104 is designed to be a highly selective dual-MEK inhibitor
that further disrupts KSR to modulate the signaling dynamics of the
MAPK pathway by driving deep cyclic inhibition that deprives tumor
cells of the sustained proliferative signaling required for rapid
growth, while providing a cadenced, moderate level of signaling
sufficient to spare healthy cells. IMM-1-104 is being developed to
treat advanced solid tumors in patients harboring RAS mutations,
and is translationally guided
by Immuneering's proprietary, human-aligned 3D tumor
modeling platform combined with patient-aligned bioinformatics. In
addition to IMM-1-104, Immuneering
is evaluating its MEK-io product candidate,
IMM-6-415, in IND-enabling studies, and has five other
oncology programs in the discovery stage that are designed to
target components of the MAPK or mTOR pathway, as well as two
discovery stage neuroscience programs.
Forward-Looking StatementsThis press release
includes certain disclosures that contain "forward-looking
statements," including, without limitation, statements regarding
Immuneering’s expectations regarding the sufficiency of
Immuneering’s cash, cash equivalents and marketable securities, its
full year GAAP operating expenses for 2022, the treatment potential
of IMM-1-104 and IMM-6-415, the timing of submission of the IND and
commencement of clinical trials for IMM-1-104 and IMM-6-415, and
Immuneering’s ability to advance its pipeline and further diversify
its portfolio and make progress towards its longstanding goal of
creating better medicines for cancer patients. Forward-looking
statements are based on Immuneering’s current expectations and are
subject to inherent uncertainties, risks and assumptions that are
difficult to predict. Factors that could cause actual results to
differ include, but are not limited to, the risks inherent in
oncology and neuroscience drug development, including target
discovery, target validation, lead compound identification, lead
compound optimization, preclinical studies and clinical trials.
These and other risks and uncertainties are described more fully in
the section titled "Risk Factors" in Immuneering’s most recent Form
10-Q filed with the U.S. Securities and Exchange Commission.
Forward-looking statements contained in this announcement are made
as of this date, and Immuneering
Corporate Contact:Rebecca Kusko,
Ph.D.Immuneering Corporation617-500-8080rkusko@immuneering.com
Investor Contact:Susan A. NoonanS.A. Noonan
Communications917-513-5303susan@sanoonan.com
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024